Greetings, and thank you for joining us for GBS, Inc's Fourth Quarter and Fiscal Yearend 2022 Financial and Business Update Conference Call. Currently all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, today's conference call is being recorded. Joining us on the call today are Dr. Steven Boyages, GBS CEO and Chairman of the Board; and Spiro Sakiris, Chief Financial Officer. A press release announcing financial results and providing a business update was issued this afternoon and is available on the GBS website at gbs.inc. If you'd like to be added to the company distribution list, please send an email to investor.relation@gbs.inc. Some of the statements on this conference call are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involves risks and uncertainties. Forward-looking statements on this call include without limitation GBS, Inc.'s ability to develop and commercialize diagnostic tests, realize commercial benefit from its partnerships and collaborations and secure regulatory approval, among others. Although GBS, Inc., believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, exceptions may prove to have been materially different from the results expressed or implied by such forward-looking statements. GBS, Inc. has attempted to identify forward-looking statements by terminology, including believe, estimates, anticipates expects, plans, projects, intends, potential, may, could, might, will, should, approximately or other words that convey uncertainty of future events or outcomes will identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors included in the company's public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of this date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after this date or to reflect the occurrence of unanticipated events. During this conference call the company may refer to EBITDA, a non-GAAP measure. EBITDA is not and should not be considered an alternative to net income/loss from operations and/or other measures for determining operating performance. EBITDA is normally calculated by adding back tax income -- back income tax, depreciation and amortization to net income/loss. I would now like to turn the floor over to Dr. Steven Boyages, CEO of GBS, Inc. Steven, please go ahead.

Thank you, Operator, and good afternoon, everyone. We appreciate you joining us today for our fiscal yearend and fourth quarter 2022 financial and business update call. Hopefully you've had the opportunity to review today's corresponding press release providing an overview of our recent achievements, important upcoming milestones and financial results for the fourth quarter ended June 30, 2022. On today's call, I would like to point out the accomplishments of this most recent quarter, as well as reflect on all we've achieved over the last 12 months. I'd also like to provide an update on our exciting, ongoing engagement with Intelligent Fingerprinting Limited for the rights to its point-of-care fingerprint, sweat-based drug screening technology, presently focused on opioids and drugs of abuse. I will then turn the call over to Spiro, our Chief Financial Officer for a review of key financial metrics, including our preliminary yearend and fourth quarter results with updated forecasted cash burn. Following a reshuffling of roles early in the year, including my appointment as CEO and Chair of the Board, the entire GBS team has successfully achieved several key milestones previously forecasted, specifically as it relates to the saliva Glucose Biosensor as our lead asset. And following IRB approval received in March we've now completed sample collection and analysis in our study of coincident sampling of oral fluid and blood to evaluate the time course of glucose. This study enrolled approximately 40 adults with Type II diabetes mellitus at the Diabetes Research Institute of Sutter Health Mills-Peninsula Medical Center in San Mateo, California, is being conducted to support clinical validation whilst also solidifying the direction of future clinical studies. I'm pleased to report that the results from that study were encouraging and in line with expectations, where blood, saliva glucose concentrations were consistent with previous studies.…

Thank you Steven. I will now provide a brief overview of GBS' full fiscal 2022 and fourth quarter financial results. As of 30 of June, 2022, the company's cash, cash equivalents and marketable securities totaled approximately $8.2 million, compared to approximately $12.6 million on June 30, 2021. For the year ended June 30, 2022, the company had a preliminary net loss of $8.4 million or $0.57 per share, compared with a net loss of $7.3 million or $0.65 per share for the same period last year. This is predominantly due to the acceleration of development and commercialization expenditures. Government support income was $437,000 and $1.98 million for the year ended 30 of June '22 and '21 respectively. Since our IPO, GBS has continued to bring forward expenditure on key resources and commercial partners to advance projects towards commercialization. The major categories include research and development and commercialization for the financial year of $3.8 million, compared to the year prior of $3.8 million also. Employee benefits expenses of $2.3 million compared to the prior year of $1.9 million, the increase being due to staff towards commercialization and development. GBS is of the view that based on the current operating plan and financial resources, its cash, cash equivalents and marketable securities at June 30, '22 will be sufficient to cover expenses and capital requirements into the second half of the 2023 calendar year. Cash runway does not include exercising the Glucose North American license option agreement. The financial strategies discussed under financial stability are being pursued in parallel. Thank you. Over to the operator.

Thank you. We will now be having our question-and-answer session. [Operator Instructions] Thank you. Our first question is from John Vandermosten with Zacks. Please proceed with your question.

Thank you, and hello, Steven, Spiro. How are you guys doing?

Good afternoon, John.

Good afternoon. So obviously the Fingerprinting deal is a pretty big deal. And I know that the -- or we know that the cutoff date was today for the arrangement that you had. But it sounds like there's an extension. What are the sticking points? And what are the other details that you are negotiating? Obviously, you probably can't share all of them with us. But just want to hear what the main discussion points that you can make public are on that.

Sure. I'll hand across to Spiro on that. But you're absolutely right. We're very excited by it. It's a long and detailed process. I was just talking to Spiro before this call. And they spent three hours negotiating. And as you stated, we can't give you all of the details, but I'll get the Spirit to give you some of the key highlights going forward.

Thank you.

Spiro, are you on mute? Seems like we have a technical problem.

I can hop on to another question. You had mentioned on the first part of the call just that there were going to be some different sampling protocols for the strip. And I'm just wondering if you could let us know kind of what those are. I mean, just to get an idea of how they might differ. Obviously, that'll come into play when people are actually using them after approval. How does that look?

Sure, sure. So the initial study was not done on the strip. The initial Mateo study that we talked about in the in the script here was based on saliva using a mass spectrometer and doing glucose measurements in venous blood and capillary blood using the standard methodologies. But the exciting element of that was that it was detectable. It was in line with the previous published results. Paul Dastoor, our Chief Scientist and Innovator was very excited. And we're now proceeding apace onto milestone eight. These studies will then further look at all the variables that may affect glucose availability in saliva. And using the actual Biosensor to actually measure that glucose sample in the saliva itself. From a technical perspective, it's a matter of then trying to improve the sensitivity of the strips by looking at the chemical and conductive layers within the strip. And that's part of the next SRA that's been negotiated with the University of Newcastle. So we expect that to be completed within the next two quarters. But so far, we're extremely excited by the initial results.

Okay, very good. And Steven, since I got you on the line, you're Interim CEO, and I'm just wondering if that -- is that going to continue on? Are you going to assume the full CEO role? What should we think about in terms of that?

Look, at the moment we just want to complete the IFP deal. Assuming that will be completed within the next month or two, our teams are going across to U.S. and then the UK as well to have a look at the Cambridge site where IFP is based. And once we have some management representation with some Board representation, from IFP and you [ph] both point of view, then we will look at the Chief Executive position. But at the moment, it's business as usual. We're expanding, as you can see with our Director of Operations, Peter Passaris and Spiro Sakiris and Harry Simeonidis are doing a fantastic job. The company is growing in terms of numbers and activity and productivity.

Okay, thank you for the management update. And I don't know if Spiro's back, is he available?

Yes. Can you hear me?

Oh, yes. Perfect. I can hear you.

Alright, so good. Thank you.

Yes, I wanted to just get a sense of that -- I actually can't remember what my first question was, but I was trying to get a sense of just cash burn and kind of how adding the new deal if you add on Intelligent Fingerprinting, how that's going to change cash flow going forward after they're layered on, assuming the deal takes place.

Yeah. And your other part, I can jump. The sticking points -- some of the sticking points are the key directions going forward.

Right, exactly. That's right. Yeah. Yeah. Yeah, the key sticking points going forward. And then assuming it does get done, how's that going to change the cash flow view going forward, because I know there revenue is positive. So it just be helpful to understand how that fits in.

Yes, can you hear me now?

I sure can.

Oh, good. Okay, good. So let me get through those questions. So the first point is you asked before in relation to the 31 of August deadline. So what that 31 of August deadline is, just to clarify, that is when the right to IFP to come into the exclusivity component of it. They -- after the 31 of August, they can then go forward and see through the exclusivity component of it. So it doesn't put -- it's not actually a deadline as we speak. And there's been no intention coming to exclude that or to set [ph] the exclusivity period. So that's pressing on. Discussions are ongoing. And we're just basically going through a lot of the detail, the fine points, are putting something together like this. There's quite a few points that have to be addressed and that's been looked at as we speak. So we're pressing on with that. And many late nights, John dealing with the different time zones and what have you, so but we're pressing forward. The second question, sorry, I think you were discussing in relation to the cash burn. So what's happening in the cash burn situation is a benefit with our cash burn is that we have clumpy nature of expenditure with R&D, with equipment and so forth. So what will happen is, we've got the ability to extend the cash burn in relation to that type of expenditure with the timing of that expenditure. So what we're looking at doing is once all goes well, we anticipate that the deal does come off, we'll be going back and doing pro formas and releasing that to the market, in relation to the impact on the cash flow, but bearing in mind that we do have that flexibility in relation to the clumpy and project-based nature of our expenditure.

Okay, and then kind of along that same line, you're getting some funds to support the building of the facility. What cash flow should we expect related to that to come in?

Yeah, good point. So what we've got with that is in relation to the building, so what's happening is the building -- the discussions are that the university will be putting the building up, and then we will be taking that on as a tenant. And that's part of the discussion. So there's no capital outlay in relation to the construction. The capital outlay comes into it in relation to the equipment. Now that's why we've started -- as Steve covered it before, we've started ordering the equipment, being mindful that we want to commission the equipment, have it going without losing time. Now that expenditure has already commenced, which is in the current cash flow numbers that we've been through. And then the timing of that coming in, the impact of that, as we make the expenditure, we get matched with that government grants of the MMI facility from the government dollar for dollar. So that's where the nature of the expenditure -- we're bringing forward the parts of the equipment that we need now, which are important, and then we're timing the rest of it by order of priority and matching the cash inflows and outflows as well too.

Okay, and just going back to the -- I think you guys had mentioned that 60% of the equipment was going to be in before the end of the year. Is that in dollar terms? Or is that in kind of, I guess, quantity of equipment?

Yes, quantity, that's quantity. What you'll find is expensive pieces of equipment that come in towards the end. And what we're doing is the equipment is being staged according to A, completing the development stage. And then the final part of the equipment is moving into the hardcore manufacturing stage.

Okay, so in terms of cash flows for the equipment is it more like 50-50, I guess, before yearend '22, and then after yearend 22?

Probably yeah -- I would say for 2022, that's probably a fair estimate, sort of 50-50 Look, having said that may be more like 40-60 because the expensive items of equipment, which we're planning to do towards the end of that period.

Great. That is helpful. Thank you guys for taking my questions.

Thank you, John.

Thank you.

Thank you. There are no further questions at this time. I would like to turn the floor back over to Dr. Boyages for any closing comments.

Thank you operator. In closing, I just want to reiterate our continued commitment and strong belief in innovative actionable Biosensors for point-of-care monitoring diagnosis as being integral to the future of all healthcare. Those suffering from diabetes deserve more affordable, convenient and disposable testing options which GBS aims to deliver whilst also reducing costs to all stakeholders, including not only patients but providers and payers as well. Finally, I'd like to thank the entire GBS team for their tireless effort and dedication, along with patients and investigators from our studies. And equally, it's important the continued support of our shareholders. Please visit us online for more information at gbs.inc or reach out to our investor relations department with any further questions.

This concludes today's conference. You may disconnect your lines at this time. Thank you for your participation.